登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>Bevacizumab >BEB-Y12

Anti-Bevacizumab Antibody (AY12) (recommended for neutralizing assay)

抗体来源(Source)

Anti-Bevacizumab Antibody (AY12) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

克隆号(Clone)

AY12

种属(Species)

Mouse

亚型(Isotype)

Mouse IgG1/kappa

抗体类型(Antibody Type)

Hybridoma Monoclonal

种属反应性(Reactivity)

Human

免疫原(Immunogen)

Bevacizumab.

特异性(Specificity)

Recognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies.

应用(Application)

ApplicationRecommended Usage
ELISA0.1-100 ng/mL

纯度(Purity)

>95% as determined by SDS-PAGE.

纯化(Purification)

Protein A purified/ Protein G purified

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Bevacizumab SDS-PAGE

Anti-Bevacizumab Antibody (AY12) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-ELISA

Bevacizumab ELISA

Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 5 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 62 ng/mL (QC tested).

Protocol

Bevacizumab ELISA

Demonstration of the specificity of Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12) to the bevacizumab.

Protocol

Bevacizumab ELISA

Measured by its neutrlizing ability in a functional ELISA. Immobilized bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibody (AY12) (Cat. No. BEB-Y12) and Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a inhibition rate of 96%.

Protocol

 

活性(Bioactivity)-SPR

Bevacizumab SPR

Anti-Bevacizumab Antibody (AY12) (mouse IgG1, Cat. No. BEB-Y12) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 0.08 nM.

Protocol

 

背景(Background)

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定